Characteristics and Treatment Patterns of Patients with Diabetic Macular Edema Non-Responsive to Anti-Vascular Endothelial Growth Factor Treatment in Ontario, Canada

References

• Ratra D. Commentary: switching of anti-vascular endothelial growth factor agents in refractory diabetic macular edema. Indian J Ophthalmol. 2021;69(2):367–368. doi:10.4103/ijo.IJO_2611_20
   PubMed Web of Science ®Google Scholar
• Furino C, Boscia F, Reibaldi M, Alessio G, Mencía-Gutiérrez E. Intravitreal therapy for diabetic macular edema: an update. J Ophthalmol. 2021;2021:6654168. doi:10.1155/2021/6654168
   PubMed Web of Science ®Google Scholar
• Chen YP, Wu AL, Chuang CC, Chen SN. Factors influencing clinical outcomes in patients with diabetic macular edema treated with intravitreal ranibizumab: comparison between responder and non-responder cases. Sci Rep. 2019;9(1):10952. doi:10.1038/s41598-019-47241-1
   PubMed Web of Science ®Google Scholar
• Busch C, Fraser-Bell S, Gilaki M, et al. Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetic. 2019;56(12):1341–1350. doi:10.1007/s00592-019-01416-4
   PubMed Web of Science ®Google Scholar
• Sorour OA, Levine ES, Baumal CR, et al. Persistent diabetic macular edema: definition, incidence, biomarkers, and treatment methods. Surv Ophthalmol. 2023;68(2):147–174. doi:10.1016/j.survophthal.2022.11.008
   PubMed Web of Science ®Google Scholar
• Gonzalez VH, Campbell J, Holekamp NM, et al. Early and long-term responses to anti-vascular endothelial growth factor therapy in diabetic macular edema: analysis of Protocol I data. Am J Ophthalmol. 2016;172:72–79. doi:10.1016/j.ajo.2016.09.012
   PubMed Web of Science ®Google Scholar
• DRCR Retina Network. Protocol I. Available from: https://public.jaeb.org/drcrnet/stdy/146. Accessed March 10, 2023.
   Google Scholar
• Dugel PU, Campbell JH, Kiss S, et al. Association between early anatomic response to anti-vascular endothelial growth factor therapy and long-term outcome in diabetic macular edema: an independent analysis of protocol I study data. Retina. 2019;39(1):88–97. doi:10.1097/IAE.0000000000002110
   PubMed Web of Science ®Google Scholar
• Downey L, Acharya N, Devonport H, et al. Treatment choices for diabetic macular oedema: a guideline for when to consider an intravitreal corticosteroid, including adaptations for the COVID-19 era. BMJ Open Ophthalmol. 2021;6(1):e000696. doi:10.1136/bmjophth-2020-000696
   PubMed Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Maguire MG, et al. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in Protocol T. Am J Ophthalmol. 2018;195:93–100. doi:10.1016/j.ajo.2018.07.030
   PubMed Web of Science ®Google Scholar
• Salumi A, Vila N, Mo Dabber M, Kapusta M. One-year outcomes of aflibercept for refractory diabetic macular edema in bevacizumab nonresponders. Indian J Ophthalmol. 2021;69(2):360–367. doi:10.4103/ijo.IJO_459_20
   PubMed Web of Science ®Google Scholar
• Lim LS, Ng WY, Mathur R, et al. Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab. Clin Ophthalmol. 2015;9:1715–1718. doi:10.2147/opth.S81523
   PubMed Web of Science ®Google Scholar
• Rahimy E, Shahlaee A, Khan MA, et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol. 2016;164:118–127.e2. doi:10.1016/j.ajo.2015.12.030
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077:e35. doi:10.1016/j.ophtha.2010.02.031
   PubMed Web of Science ®Google Scholar
• Regillo CD, Callanan DG, Do DV, et al. Use of corticosteroids in the treatment of patients with diabetic macular edema who have a suboptimal response to anti-VEGF: recommendations of an expert panel. Ophthalmic Surg Lasers Imaging Retina. 2017;48(4):291–301. doi:10.3928/23258160-20170329-03
   PubMed Web of Science ®Google Scholar
• Elnahry AG, Noureldine AM, Abdel-Kader AA, et al. Optical coherence tomography angiography biomarkers predict anatomical response to bevacizumab in diabetic macular edema. Diabetes Metab Syndr Obes. 2022;15:395–405. doi:10.2147/DMSO.S351618
   PubMed Web of Science ®Google Scholar
• Kulikov AN, Sosnovskii SV, Berezin RD, et al. Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study. Clin Ophthalmol. 2017;11:1995–2002. doi:10.2147/OPTH.S146019
   PubMed Web of Science ®Google Scholar
• Grzybowski A, Markeviciute A, Zemaitiene R. Treatment of macular edema in vascular retinal diseases: a 2021 update. J Clin Med. 2021;10(22):5300. doi:10.3390/jcm10225300
   PubMed Web of Science ®Google Scholar
• Chatziralli I. Editorial - Suboptimal response to intravitreal anti-VEGF treatment for patients with diabetic macular edema: is there any point in switching treatment? Eur Rev Med Pharmacol Sci. 2018;22(15):5047–5050. doi:10.26355/eurrev_201808_15648
   PubMed Web of Science ®Google Scholar
• Lai CT, Hsieh YT, Lin CJ, et al. Age, initial central retinal thickness, and OCT biomarkers have an influence on the outcome of diabetic macular edema treated with ranibizumab- Tri-center 12-Month Treat-and-Extend Study. Front Med. 2021;8:668107. doi:10.3389/fmed.2021.668107
   Web of Science ®Google Scholar
• Kuroiwa DAK, Malerbi FK, Regatieri CVS. New insights in resistant diabetic macular edema. Ophthalmologica. 2021;244(6):485–494. doi:10.1159/000516614
   PubMed Web of Science ®Google Scholar
• Everett LA, Paulus YM. Laser therapy in the treatment of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2021;21(9):35. doi:10.1007/s11892-021-01403-6
   PubMed Web of Science ®Google Scholar
• Chauhan MZ, Rather PA, Samarah SM, Elhusseiny AM, Sallam AB. Current and novel therapeutic approaches for treatment of diabetic macular edema. Cells. 2022;11(12):1950. doi:10.3390/cells11121950
   PubMed Web of Science ®Google Scholar